CRL vs DNA
CRL: Charles River Laboratories is a global, non-clinical contract research organization that partners with life sciences companies to streamline drug discovery and development. DNA: Ginkgo Bioworks provides an AI-enabled, robotically automated platform designed to make biological research, cell programming, and manufacturing easier and faster for its customers.
Side-by-side fundamentals
| Metric | CRL | DNA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $298.00 | $11.34 | |
| Market cap | $14.2B | $722M | |
| Net margin FY2025, SEC XBRL | -3.6% | -183.8% | CRL higher |
| Operating margin FY2025, SEC XBRL | +0.6% | -185.3% | CRL higher |
| ROE FY2025, SEC XBRL | -4.6% | -61.5% | CRL higher |
| ROA FY2025, SEC XBRL | -2.0% | -27.9% | CRL higher |
| Debt / equity as of 2026-09-03 | 0.93 | 0.00 | DNA lower |
| Revenue growth (YoY) as of 2026-09-03 | -0.7% | -40.5% | CRL higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | -29.1% | CRL higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.37 | 2.35 | |
| 1-year return as of 2026-10-08 close | +71.8% | -29.5% | CRL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.